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ABSTRACT
Objectives: Labor induction is indicated in 20% to 40% of pregnancies. Over half of pregnancies qualified for the induction 
of labor require stimulation of the cervix to ripen. The drug used increasingly more often in pre-induction is the PGE-1 pros-
taglandin analog — misoprostol 200 μg.
Material and methods: The study includes a total of 100 patients qualified for labor pre-induction with Misodel® (miso- 
prostol 200 μg vaginal insert). The study group comprises two subgroups: primigravidas and multiparas. Assessments 
included: indications for labor pre-induction, time from Misodel application to delivery, caesarean section rate and indica-
tions, duration of first and second stage of labor, rate of vaginal deliveries, need for oxytocin or fenoterol administration 
side effects and newborn condition.
Results: The most common indication for labor induction was gestational diabetes and pregnancy past term. The average 
time to vaginal delivery was 14 h 45 min, time to the onset of active phase of labor — 11 h 45 min, time to membranes’ 
rupture — 15 h, time to vaginal delivery — 14 h 18 min. The times of multiparas were significantly shorter. The rate of vaginal 
deliveries within 12 hours amounted to 42.42%, while within 24 hours it reached 83.33%. The overall caesarean section 
rate was 33%. The most common indication for caesarean section was the risk of intrauterine hypoxia. Tachysystole and 
hyperstimulation was observed in 4% of cases, while abnormalities in the cardiotocographic tracing in 43%.
Conclusions: Misodel is an effective method for labor pre-induction, without affecting the caesarean section rate and has 
no adverse effect on the newborn condition.
Key words: labor, induction, preinduction, pregnancy, prostaglandins, misoprostol
Ginekologia Polska 2017; 88, 11: 606–612
Corresponding author:
Iwona Jagielska
Department of Obstetrics and Gynecology
L. Rydygier Collegium Medicum in Bydgoszcz
Nicolaus Copernicus University, Bydgoszcz, Poland
e-mail: iwonajagielska@o2.pl
INTRODUCTION
Induction of labor is an obstetric procedure that is used 
increasingly more often (20–40% of pregnancies) [1–7]. The 
reason for that may be the increased proportion of pregnant 
patients with a chronic condition (for instance obesity, hy-
pertension, diabetes mellitus) and the advancements in 
diagnostic methods during prenatal care that allow early 
detection of threats to fetal well-being [1, 4]. This is relevant 
since labor induction is indicated when the risks for mother 
and/or fetus of continuing pregnancy outweigh the risks of 
resolving it. The aim of induction is to stimulate contractions, 
hence labor and vaginal delivery within 12 to 24 hours [8, 
9]. Whether induction is successful depends on the cervix 
maturity, which is assessed usually with a modified Bishop 
score. When the cervix is not mature, pre-induction is re-
quired for the cervix to ripen [1, 5, 10]. Different methods 
can be used for pre-induction including mechanical (Foley 
catheter or Cook balloon) and pharmacological (prostaglan-
dins) [1, 2, 5, 8, 10]. The WHO and FDA recommend the use 
of prostaglandins in labor induction and pre-induction for 
numerous reasons. Most studies confirm high efficacy of 
prostaglandins in inducing labor within 24 hours with no 
related increase in caesarean section rate and with lower 
oxytocin use. Factors to be taken into account are the risk 
of overstimulation and uterine tachysystole as well as the 
contraindications for prostaglandin use such as previous 
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caesarean section or other surgical intervention on the ute-
rus [1–3]. The misoprostol vaginal insert (MVI) containing 
200 [μg] of misoprostol is a novel product that releases 
the PGE1 synthetic analog at the rate of 7 μg per hour for 
24 hours [12]. Since misoprostol has a dual action, it is clini-
cally both a pre-induction agent and a factitious induction 
agent at the same time, since it stimulates ripening of cervix 
through remodeling and it acts on uterine smooth muscle 
cells promoting their contraction [12].
The aim of this paper is to assess the effectiveness and 
safety of labor pre-induction with the use of 200 μg miso-
prostol vaginal insert. 
MATERIAL AND METHODS
The study group comprises 100 pregnant women ad-
mitted to Obstetrics Clinic in Bydgoszcz, Poland, between 
the 15th of May 2015 and the 30th of January 2017 who 
underwent pre-induction with MVI. Information about the 
patients and the course of labor was obtained from the ho-
spital’s documentation. The inclusion criteria are as follows: 
single pregnancy; gestation of at least full 36 weeks; longi-
tudinal lie with cephalic presentation; Bishop score < 4. The 
exclusion criteria are: placental pathology; unexplained va-
ginal bleeding; intrauterine infection; abnormal FHR tracing; 
previous caesarean section or other surgical intervention on 
the uterus; any other condition for which natural delivery 
is contraindicated. We obtained informed consent from all 
patients participating in the study. Before MVI application, 
the cervix maturity was estimated with modified Bishop 
score. Nonstress test was performed for at least 30 minutes 
both before and after the application of misoprostol. The 
MVI was removed at the start of: regular contractions, active 
phase of labor (dilation ≥ 4 cm), tachysystole occurrence, 
hyperstimulation or abnormal cardiotocography tracing. 
In concordance with the producer’s indications, the MVI 
was removed after 24 hours the latest. If contractions were 
still absent after 30 minutes from the removal of MVI, the 
patient was administered oxytocin IV with constant infu-
sion pump in the labor room, as recommended by Polish 
Society of Gynecologists and Obstetricians. The study group 
was subdivided into Primigravidas and Multiparas. When 
analyzing groups we assessed the following parameters: 
indications for labor induction; time from MVI to vaginal 
or other delivery; the rate of vaginal delivery after 12, 24, 
36 and 48 hours; time to rupture of membranes; duration 
of first and second stage of labor; rate of caesarean sections 
including indications; the use of oxytocin and fenoterol; 
adverse events such as hyperstimulation, tachysystole, me-
conium stained amniotic fluid; reasons for MVI removal. 
Also, fetal parameters were assessed including birth we-
ight, Apgar score and umbilical blood pH. The results were 
compared between the subgroups. The statistical analysis 
was performed with the use of Statistica 13.0 software from 
Dell Inc. The differences were tested with Student’s t-test. 
Interdependence of categorical variables was measured 
with a non-parametric Chi2 test. Statistical significance was 
set at p < 0,05 and marked with an asterisk. 
The Bioethics Committee has approved the study and 
the authors report no conflict of interest.
RESULTS
MVI was used in a total of 100 patients, which constitute 
3.5% of all delivering patients in the clinic during the study 
period. The primigravidas constitute 69% of the study group. 
The multiparas were older and had a better Bishop score 
(p < 0.05). The median duration of pregnancy was 40 weeks 
(range = 36–42) (Table 1). The most common indication for 
induction was term pregnancy complicated with gestational 
diabetes for both the study group and the multipara subgro-
up (35% and 41% respectively) and a continued pregnancy 
past 41 weeks for the primigravida subgroup (Table 2). The 
average time to any sort of delivery (irrespectively of mode 
of delivery) amounted to 14 hours and 20 minutes, while 
that to vaginal delivery was almost the same — 14 hours and 
45 minutes. The labor of multiparas was shorter by about 
2 hours than that of primigravidas (p < 0.05). The regular con-
tractions and/or the active phase of labor for multiparas and 
primigravidas initiated after on average 11 [h] and 45 [min] 
and 12 [h] and 18 [min] respectively. Both labor stages (first 
and second) were shorter in the multipara subgroup. The 
removal of MVI usually took place after 12 [h] and 38 [min]. 
A premature rupture of membranes before second stage 
Table 1. Demographic characteristics 
The study group
(n = 100)
Primigravidas
(n = 69)
Multiparas
(n = 31) p-value
Age (years) 28.91 ± 5.78 27.71 ± 5.45 31.58 ± 5.68 0.0016*
Gestational age (weeks) 40 ± 1 40 ± 1 40 ± 1 0.8944
BMI [kg/m2] 30.37 ± 4.99 30.12 ± 5.03 30.92 ± 4.94 0.4637
Bishop score 1.47 ± 1.19 1.29 ± 1.21 1.87 ± 1.06 0.0235*
*Statistically significant
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of labor was observed in 51% after on average 15 [h] and 
16 [min] (Table 3).
The most common mode of delivery in the study gro-
up was vaginal (67%) (Table 4). Only 2 cases required for-
ceps. When the subgroups are analyzed, the vaginal deli-
very constituted respectively 84% and 59% for multiparas 
and primigravidas respectively. The latter had a higher 
caesarean rate compared to multiparas (40.58% vs. 16.13%). 
Almost all caesarean sections were performed at first stage 
of labor (nearly 88%) while the most common indication 
was risk of intrauterine hypoxia and stagnant first stage 
of labor (66.66% and 12.12% respectively) (Table 5). The 
proportion of pre-inductions that led to delivery within 
48 hours irrespectively of mode of delivery reached 97%. 
In turn, within only 12 hours from MVI application such 
proportion was 57% and 31% for multiparas and primigra-
vidas respectively (p < 0.05). For the remaining time spans 
(24 and 36 [h] after pre-induction) the differences were 
not statistically significant (Table 6). Table 7 also presents 
proportions of deliveries within 12, 24, 36 and 48 [h] after 
MVI application, but they concern only vaginal mode of 
delivery. In this case 100% of deliveries took place within 
48 hours from pre-induction. Nearly 90% of multiparas 
and nearly 80% of primigravidas delivered within 24 hours 
from pre-induction. In turn, within only 12 hours many 
more multiparas delivered (64%) compared to primiparas 
(29.27%). The most common adverse event observed was 
the abnormal cardiotocograph (43%), which was an indi-
Table 2. Indications for labor induction
Indications The study group(n = 100)
Primigravidas
(n = 69)
Multiparas
(n = 31)
GDM/PGDM
Hbd 40 + 0 35 (35.00%) 22 (31.88%) 13 (41.94%)
Late term pregnancy
Hbd 41 + 1 28 (28.00%) 20 (28.99%) 8 (25.81%)
Hypertension/preeclampsia 14 (14.00%) 10 (14.49%) 4 (12.90%)
IUGR 7 (7.00%) 5 (7.25%) 2 (6.45%)
Intrahepatic cholestasis of pregnancy 6 (6.00%) 4 (5.80%) 2 (6.45%)
Hemolytic disease of the fetus 3 (3.00%) 2 (2.90%) 1 (3.23%)
Other 7 (7.00%) 6 (8.70%) 1 (3.23%)
Table 3. Pre-induction with MVI — time to end-points
Parameter The study group (hours and minutes)
Primigravidas 
(hours and minutes)
Multiparas 
(hours and minutes) p-value
Time from vaginal insert to regular uterine 
contractions or active phase of the labor 11 h 45 min ± 6 h 52 min 12 h 18 min ± 7 h 13 min 10 h 38 min ± 6 h 4 min 0.2808
Time from vaginal insert to amniotic fluid rupture 15 h 0 min ± 16 h 28 min 16 h 27 min ±19 h 40 min 12 h 4 min ± 5 h 5 min 0.1275
Time from vaginal insert to removal of MVI 12 h 38 min ± 6 h 23 min 12 h 50 min ± 6 h 2 min 12 h 2 min ± 6 h 24 min 0.6596
Duration of the first stage of labor 3 h 45 min ± 2 h 3 min 4 h 17 min ± 132.17 2 h 50 min ± 1 h 24 min 0.0041*
Duration of the second stage of labor 31 min ± 31 min 42 min ± 33 min 11 min ± 13 min 0.0001*
Time to vaginal delivery 14 h 45 min ± 7 h 28 min 13 h 36 min ± 7 h 55 min 11 h 43 min ± 5 h 36 min 0.0089*
Time to any delivery 14 h 20 min ± 7 h 2 min 18 h 34 min ± 19 h 56 min 13 h 3 min ± 7 h 47 min 0.1292
*Statistically significant; MVI — misoprostol vaginal insert
Table 4. Mode of delivery after MVI
Parameter The study group(100%)
Primigravidas
(100%)
Multiparas
(100%) p-value chi
2
Unassisted vaginal birth 65.00% 56.52% 83.87%
0.0269*Forceps-assisted vaginal birth 2.00% 2.90% 0.00%
Cesarean delivery 33.00% 40.58% 16.13%
*Statistically significant; MVI — misoprostol vaginal insert
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cation for caesarean section in half of the cases. Complica-
tions that are potentially dangerous to mother and fetus 
(tachysystole and hyperstimulation) were observed in 4% of 
patients only (Table 8). Oxytocin was used in 56% of patients 
while fenoterol in 19%. Remifentanil and oxytocin was 
used significantly more often in primigravidas compared 
to multiparas (Table 9). Figure 1 shows a percentage break- 
down of the reasons for MVI removal. The most common 
indication for removal was the initiation of active phase of 
labor or the start of regular contractions (72%). Only 9% 
of patients required the MVI to be removed after 24 hours. 
Table 10 presents fetal outcomes. 85% of newborns had 
Apgar score > 8. The overall average was 9 while the overall 
pH was 7.29. Only 2 newborns were in a severe condition. 
Table 5. Indications for caesarean section
Indications The study group(n = 33)
Primigravidas
(n = 28)
Multiparas
(n = 5)
Cardiotocography abnormalities 22 (66.66%) 19 (67.86%) 3 (60.00%)
Failure to progress during the first stage of labor 4 (12.12%) 2 (7.14%) 2 (40.00%)
Failure to progress during the second stage of labor 1 (3.03%) 1 (3.57%) 0 (0.00%)
Uterine hyperstimulation 2 (6.06%) 2 (7.14%) 0 (0.00%)
Failed induction 3 (9.09%) 3 (10.71%) 0 (0.00%)
Threatened intrauterine infection 1 (3.03%) 1 (3.57%) 0 (0.00%)
Table 6. Successful induction with MVI — any delivery
The study group
(100%)
Primigravidas
(100%)
Multiparas
(100%) p-value
Delivery within 12 h of induction 38.14% 30.84% 56.67% 0.0269*
Delivery within 24 h of induction 83.50% 80.09% 90.00% 0.4889
Delivery within 36 h of induction 96.91% 95.52% 100% 0.5872
Delivery within 48 h of induction 97.94% 97.01% 100% 0.8546
*Statistically significant; MVI — misoprostol vaginal insert
Table 7. Successful induction with MVI — vaginal deliveries
The study group
(100%)
Primigravidas
(100%)
Multiparas
(100%) p-value
Delivery within 12 h of induction 43.28% 29.27% 65.38% 0.0056*
Delivery within 24 h of induction 83.58% 78.05% 92.31% 0.2565
Delivery within 36 h of induction 98.51% 97.56% 100% 0.8012
Delivery within 48 h of induction 100% 100% 100% 1.0000
*Statistically significant; MVI — misoprostol vaginal insert
Table 8. Adverse events after MVI
Outcome The study group(100%)
Primigravidas
(100%)
Multiparas
(100%)
Cardiotocography abnormalities 43.00% 47.83% 32.26%
Gastrointestinal disorder 1.00% 1.45% 0.00%
Postpartum hemorrhage 1.00% 1.45% 0.00%
Uterine tachysystole 2.00% 1.45% 3.23%
Uterine hyperstimulation 2.00% 2.90% 0.00%
Meconium in amniotic fluid 5.05% 7.35% 0.00%
MVI — misoprostol vaginal insert
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DISCUSSION
Out of pregnancies that have indications for labor in-
duction over 50% require pre-induction for the cervix to 
ripen [13, 14]. The literature is rich is articles that compare 
and assess the effectiveness and safety of pre-induction 
methods involving prostaglandins such as dinoprostone gel 
and vaginal insert or misoprostol in form of tablets or inserts 
[7, 15–19]. Misoprostol tablets are registered in Europe for 
the prevention and treatment of gastric ulcers only. Howe-
ver, Polish Society of Gynecologists and Obstetricians has 
approved its use in labor induction in case of fetal demise 
[5, 9]. This shows that the registration of misoprostol vaginal 
insert for pre-induction had increased the optimal choice 
options. This paper presents obstetric outcomes of 100 pre-
gnancies where MVI was used. Similarly to other studies, the 
assessment of drug effectiveness was estimated in light of 
time to vaginal delivery and the vaginal delivery rate within 
12, 24, 36, 48 hours. Safety assessment in turn was based on 
caesarean section rate and newborn’s condition [2–4, 15, 17, 
20]. The results of this study concerning average age, parity 
and duration of pregnancy are comparable to the results 
reported in literature [4, 6, 21, 22]. Yet, similarly to studies of 
Wing et al., Tsicouras et al. or that of Kosińska-Kaczyńska et 
al., in our study the primigravidas prevail (65–82%), which 
is associated with the cervix being more immature in that 
subgroup, hence more often selected for pre-induction [2, 
3, 7, 23]. To support this, we show that the Bishop score in 
our study was significantly higher compared to the multi-
paras subgroup. 
Usually, the most common indications for labor induc-
tion are pregnancies beyond term, diabetes and preec-
lampsia [1, 2, 22, 24]. Similarly, the most common indica-
tions during this study were term pregnancies complicated 
with gestational diabetes and continuous pregnancies past 
41 weeks. Many authors regard the pre-induction with mi-
soprostol as a very effective method in case of premature 
rupture of membranes (PROM) [25]. In the study of Mayer 
et al. PROM was the second most common indication for the 
pre-induction with misoprostol [16]. In contrast, in our clinic 
such indication was made in 2% of cases only. This difference 
was most probably caused by insufficient experience of our 
doctors in pre-induction with MVI. 
Most studies confirm that prostaglandins are superior 
to mechanical methods in pre-induction and induction of 
labor, while misoprostol is superior to dinoprostone [2, 3, 
14, 17, 20, 22, 26]. Vaginal delivery in shortest time possible 
is the aim of every induction. In this study the average time 
to vaginal delivery amounted to 14 [h] and 45 [min] and was 
significantly longer than that of multiparas (11 [h] 43 [min]). 
Table 9. Pharmacotherapy during labor pre-induced with MVI
The study group
(n = 100)
Primagravidas
(n = 69)
Multiparas
(n = 31) p-value
Oxytocin 50 (50.00%) 39 (56.52%) 11 (35.48%) 0.0517
Fenoterol 19 (19.00%) 18 (26.09%) 1 (3.23%) 0.0070*
Remifentanil 18 (18.00%) 16 (23.19%) 2 (6.45%) 0.0439*
*Statistically significant; MVI — misoprostol vaginal insert
Table 10. Newborn outcomes after MVI 
The study group
(n = 100)
Primigravidas
(n = 69)
Multiparas
(n = 31) p-value
Newborn weight [g] 3338 ± 487 3348 ± 466 3318 ± 536 0.7784
Apgar score [points] 9.00 ± 1.88 8.88 ± 2.07 9.26 ± 1.37 0.2877
pH 7.29 ± 0.09 7.29 ± 0.09 7.30 ± 0.09 0.4367
MVI — misoprostol vaginal insert
Figure 1. The reason for removing misoprostol vaginal insert
Regular uterine contractions
Active phase of the labour
Amniotic uid rupture
Planned removing
Hiperstimulation
Fetal heart rate abnormalities
Other
32%
40%
7%
9%
8%2%
2%
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Other authors report comparable results [7, 16, 18, 21]. In our 
clinic the study yields a vaginal delivery rate within 12 ho-
urs equal to 43.28% and within 24 hours equal to 83.58%. 
However, in the study of Wing et al. and that of Draycott et 
al. the rate of vaginal deliveries within 24 hours was lower 
and amounted to 54.6% and 56%, respectively to the study 
[3, 18]. Moreover, our vaginal delivery rate within 12 hours 
was higher in multiparas (p < 0.05), while the rate within 
24 hours converged between the groups. Also, in our study 
group over half of patients were observed to have PROM 
before the onset of second stage of labor, usually after 15 [h] 
16 [min]. Górnisiewicz et al. compared the effectiveness of 
misoprostol with dinoprostone and found the time to PROM 
in MVI pre-induced group in to be shorter (9 [h] 18 [min]) [7]. 
In choosing the optimal method for pre-induction, apart 
from effectiveness, also safety for the mother and the fetus 
plays a role. Most of researchers believe that labor induction 
is associated with higher operative rates and induction 
failure [5, 9]. Many authors focus on the increased caesa-
rean section rate in the setting of labor induction [23, 27, 28]. 
The Genesis study involving 2336 patients confirms a higher 
caesarean section rate in the primigravidas with induced 
labor compared to spontaneous labor (31% vs. 36%) [27]. 
It seems however that the caesarean section rate can be 
minimized when patient is qualified properly, especially 
in case of pregnancies past the estimated delivery date [6, 
10, 28]. Pregnancies that require labor induction are often 
complicated with concomitant conditions like preeclampsia, 
hypertension or gestational diabetes, which as such increase 
the risk of caesarean section rate. In our clinic, from among 
all deliveries since 2016, the rate of caesarean section has 
been at the level of 42%. Meanwhile, patients with MVI in 
our study had a lower caesarean section rate that equaled 
33%. Yet, we observed this rate to be relatively higher in the 
primigravida group (40.58% vs. 16.13%) and in the group 
with concomitant preeclampsia or diabetes. However, other 
authors report the caesarean section rate after pre-induction 
with MVI to be even lower — from 22.9% to 27.1% [19, 24]. 
Similarly to other studies, we report the risk of intrauterine 
fetal hypoxia to be the most common indication for a ca-
esarean section [3, 15, 24]. 
Despite the confirmed effectiveness of misoprostol in 
labor pre-induction, there considerations regarding risk 
of causing tachysystole, hyperstimulation, meconium-sta-
ined fluids or cardiotocographic abnormalities [8, 17, 18, 
22–24, 29]. In our study we recorded only 2% of cases with 
tachysystoly, same for hyperstimulation. This is a very low 
proportion compared to literature, where such rate was 
reported to reach 13% to 53% of pregnancies [3, 15, 16, 
19]. Abnormalities of cardiotocographic tracing were re-
corded in 43% of cases but less than half of them required 
caesarean section. The interpretation of the MVI effect in 
the tracing and eventual need for caesarean section should 
be cautious then. The half-life of misoprostol administered 
vaginally is below an hour and drops to a clinically irrelevant 
level within 2 hours [12]. Stephenson and Wing [14] report 
that caesarean sections were performed even 16 hours 
after tachysystole onset, which excludes the possibility of 
misoprostol to directly influence the caesarean section rate. 
When we analyzed retrospectively the documentation after 
deliveries, we found an umbilical cord factor (short cord, 
knot or nuchal cord) in all the cases with CTG abnormali-
ty. When it comes to newborns, similarly to other studies 
on misoprostol, their condition based on Apgar score and 
umbilical cord blood pH was assessed as good [3, 7, 15, 18].
Economic factors play a separate role in choosing the 
optimal treatment method. The costs are defined conditions 
such as necessity of extra drugs’ use, duration of hospitaliza-
tion, mode of delivery or eventual intensive therapy care. The 
most common extra drugs used in our study were oxytocin 
(56% of cases) and Fenoterol (19% of cases), both used more 
commonly in primigravidas. There are many studies confir-
ming a less frequent use of drugs in the setting of MVI [3, 10, 
14, 17, 20, 23]. Since the rate of deliveries in our clinic was high, 
duration of hospitalization was short and all our patients were 
discharged within 2–4 days. None of the mothers or newborns 
required staying at the intensive therapy unit. The acceptance 
of the method for induction from the patient standpoint is 
dependent on the time to delivery and the sense of safety 
related to the possibility of fast and easy removal of the me-
dication. The studies analyzing patient satisfaction show that 
time to delivery is the most important decision factor in the 
choice of induction method [30]. 
Our studies confirm high effectiveness, safety and pa-
tient satisfaction with MVI as a pre-induction method. It 
shall be noted that the literature is scant in clinical studies 
focusing on MVI, not to mention their inferior sample size. 
With this study we hope to help the obstetricians in their 
choice of a clinically optimal pre-induction method for each 
of their patients.
CONCLUSIONS
1. Misoprostol vaginal insert Misodel® 200 μg is an effective 
pre-induction method, especially in case of immature 
cervix (Bishop score < 4).
2. The most common indications for pre-induction with 
MVI are: pregnancy past term and diabetes. Further stud-
ies are needed for the use of MVI in patients with PROM. 
3. Misodel® does not increase the caesarean section rate. 
4. According to our observations, tachysystole/hyperstimula-
tion are very rare complications in pre-induction with MVI.
5. MVI has no adverse effect on the condition of the newborn. 
6. The perinatal use of MVI may be regarded as economi-
cally justified. Yet, in needs more focused studies. 
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